Step by Step

INTRODUCTION

Professional Profile Details

5/26/2026 - Medical Grand Rounds: Circulating Tumor DNA-Directed Treatment Strategies in Colorectal Cancer

QUIZ

EVALUATION

CERTIFICATE

INTRODUCTION

Credit Hours: 1.00

Target Audience:

Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.

Educational Objectives:

Upon completion of this activity, participants should be able to:

  • Apply ctDNA-guided strategies to optimize adjuvant treatment decision-making, including de-escalation for low-risk patients and escalation considerations for high-risk disease.
  • Analyze the prognostic and predictive role of circulating tumor DNA (ctDNA) in colorectal cancer to differentiate patient risk for recurrence following definitive treatment.
  • Evaluate emerging clinical trial designs and evidence supporting minimal residual disease (MRD)-directed treatment approaches, including their impact on patient outcomes and therapeutic development.

Suggested Additional Reading:

  1. Moertel, C. G., et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 322: 352-358 (1990) André, T., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 350: 2343-2351 (2004)
  2. J Natl Compr Canc Netw 2020;18(9):1230–1237
  3. Kasi et al. BMJ Open 2021, 11:e047831
  4. Kotani et al. Nature Medicine, 29, p127–134 (2023)
  5. Globocan 2022, available at https://gco.iarc.who.int/en,
  6. National Cancer Control Indicators 2018, available at https://ncci.canceraustralia.gov.au/diagnosis/distribution-cancer-stage/distribution-cancer-stage,
  7. The Lancet Oncology. 2021 Jul 1;22(7):1002-13. 4. Jeffery, Hickey, Hider. Cochrane Database of Systematic Reviews 2019, Issue 9. Art. No.: CD002200

Authors:
Jeanne Tie, MBChB, FRACP, MD — Medical Oncologist, Lower GI Research Lead, Peter MacCallum Cancer Centre
Senior Research Fellow, Walter & Eliza Hall Institute of Medical Research
Professorial Fellow, University of Melbourne, Melbourne, AUSTRALIA
Dr. Tie discloses she is a member of the CE Speakers’ Bureau for Pierre Faber, Merck Serono, MSD, and Takeda. A consultant for Haystack Oncology. A research/grant recipient from Grail, Valar, and Haystack oncology.
No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Pittsburgh School of Medicine is accredited by the ACCME to provide continuing medical education for physicians. The University of Pittsburgh School of Medicine designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Each physician should only claim credit commensurate with the extent of their participation in the activity.

Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

The University of Pittsburgh is an affirmative action, equal opportunity institution.